Summary
Unrelated cord blood (CB) units, already manufactured, fully tested and stored, are high‐quality products for haematopoietic stem cell transplantation and cell therapies, as well as an optimal starting material for cell expansion, cell engineering or cell re‐programming technologies. CB banks have been pioneers in the development and implementation of Current Good Manufacturing Practices for cell‐therapy products. Sharing their technological and regulatory experience will help advance all cell therapies, CB‐derived or not, particularly as they transition from autologous, individually manufactured products to stored, ‘off‐the shelf’ treatments. Such strategies will allow broader patient access and wide product utilisation.